Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.46 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22148093 | 0.86 | EGLN1 (0.50) | EGLN1APPMETTL3ALDH1A3KDM4E | |
| SCHEMBL3498992 | 0.84 | EGLN1 (0.50) | EGLN1PTGS1PTGS2KDM4EALDH1A1 | |
| SCHEMBL4213470 | 0.84 | EGLN1 (0.49) | EGLN1APPMETTL3ALDH1A3 | |
| SCHEMBL21033471 | 0.82 | KDM4E (0.63) | EGLN1APPKDM4EALDH1A1GAA | |
| SCHEMBL3366016 | 0.81 | RAB9A (0.64) | EGLN1METTL3KDM4EALDH1A1GAA | |
| SCHEMBL3664964 | 0.80 | EGLN1 (0.72) | EGLN1METTL3ALDH1A3ALDH1A1HPGD | |
| SCHEMBL2638074 | 0.80 | PTGS1 (0.59) | EGLN1PTGS1PTGS2APPMETTL3 | |
| SCHEMBL3716733 | 0.79 | PTGS1 (0.48) | EGLN1PTGS1PTGS2KDM4EALDH1A1 | |
| SCHEMBL7268498 | 0.78 | PTGS1 (0.54) | EGLN1PTGS1PTGS2METTL3KDM4E | |
| SCHEMBL27037517 | 0.76 | APP (0.51) | EGLN1APPMETTL3ALDH1A3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4494698-A2 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| EP-3661922-B1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-23 | — | — | EP | disclosed |
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-20 | — | — | US | disclosed |
| US-11905285-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-20 | — | — | US | disclosed |
| US-20220056028-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-24 | — | — | US | disclosed |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-09 | — | — | US | disclosed |
| CN-111349093-B | 5, 6-bicyclic compounds as WNT signal pathway inhibitors and medical application thereof | 汇瀚医疗科技有限公司 | 2021-07-02 | — | — | CN | disclosed |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2020-07-30 | — | — | US | disclosed |
| CN-111349093-A | 5, 6-bicyclic compounds as WNT signal pathway inhibitors and medical application thereof | 汇瀚医疗科技有限公司 | 2020-06-30 | — | — | CN | disclosed |
| WO-2020125759-A1 | COMPOUND AS WNT SIGNAL PATHWAY INHIBITOR AND MEDICAL USE THEREOF | 汇瀚医疗科技有限公司 | 2020-06-25 | — | — | WO | disclosed |
| WO-2020125759-A1 | COMPOUND AS WNT SIGNAL PATHWAY INHIBITOR AND MEDICAL USE THEREOF | 汇瀚医疗科技有限公司 | 2020-06-25 | — | — | WO | disclosed |
| EP-3661922-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Dyax Corp. (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019028362-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | EGLN1 710/4885PTGS1 151/4885PTGS2 441/4885 |
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | KLKB1, KLK1, KLK5 | EGLN1 710/4885PTGS1 151/4885PTGS2 441/4885 |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | EGLN1 710/4885PTGS1 151/4885PTGS2 441/4885 |
| US-20220056028-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | EGLN1 710/4885PTGS1 151/4885PTGS2 441/4885 |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | EGLN1 3080/4885PTGS1 2236/4885PTGS2 3251/4885 |
| US-11905285-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | EGLN1 710/4885PTGS1 151/4885PTGS2 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.